Sabrina Serani

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid biopsies shaping 2026 treatment.

Cancer survival hits 70% as early screening and immunotherapy advance—yet survivorship needs and Indigenous disparities demand urgent action.

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and infusion reactions while maintaining efficacy.

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion–positive NSCLC, signaling a potential new standard and expanding genomic testing.

Dr Manmeet Ahluwalia explores how precision oncology and targeted therapies are transforming brain metastases care, extending survival from months to years.

Global phase 3 trial tests safusidenib maintenance after chemoradiotherapy, aiming to delay recurrence and improve survival in IDH1-mutant astrocytoma.

FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable safety.

Brittany Dulmage, MD, discusses why a popular ingredient in hair, skin, and nails vitamins may not be a safe option for patients undergoing cancer treatment.

FDA strengthens capecitabine and 5‑FU labels: DPD deficiency can trigger fatal toxicity; consider testing, lower doses, and prompt antidote.

Phase 2 trial tests azacitidine plus venetoclax in therapy-related high-risk MDS, showing remissions and better posttransplant survival despite TP53 mutations.

TNBC care shifts to TROP2 ADCs plus immunotherapy, highlighting early relapse needs, sequencing dilem

FDA prioritizes review of datopotamab deruxtecan for treating metastatic triple-negative breast cancer, showing significant survival benefits over chemotherapy.

New data reveals CD47 expression as a key biomarker for predicting evorpacept's effectiveness in treating HER2-positive metastatic breast cancer.

January 2026 marks a pivotal month in oncology, with the FDA advancing numerous innovative therapies for challenging cancers, emphasizing precision medicine.

A large-scale analysis reveals novel predictors of survival and resistance mechanisms in metastatic breast cancer treated with T-DXd, enhancing patient stratification.

The FDA reviews ivonescimab for advanced lung cancer treatment, showing promising trial results and potential to enhance patient outcomes post-TKI therapy.

NCCN updates guidelines to include sacituzumab govitecan as a first-line treatment for metastatic triple-negative breast cancer, enhancing patient options.

New clinical data reveals Bria-IMT's potential to significantly extend survival in patients with heavily pretreated metastatic breast cancer, offering hope for better outcomes.

Phase 2 trial shows abemaciclib prolongs disease control in recurrent high‑grade meningioma with NF2/CDK alterations, with 58% PFS at 6 months.

A virtual collaborative care model enhances mental health support in oncology, improving patient outcomes and addressing care disparities in underserved populations.

Deb Schrag, MD, emphasizes AI's role in enhancing cancer care, addressing early-onset cancers, and improving workforce well-being as she prepares for ASCO leadership.

A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in patients with untreated metastatic triple-negative breast cancer.

The FDA reviews gedatolisib, a promising treatment for advanced breast cancer, aiming to enhance patient outcomes with innovative combination therapies.

EMA validates T-DXd and pertuzumab for first-line HER2-positive metastatic breast cancer, potentially transforming treatment standards in the EU.

A new study reveals that savolitinib and osimertinib significantly enhance survival in advanced EGFR-mutated lung cancer, outperforming traditional chemotherapy.

New research highlights the potential of nogapendekin alfa inbakicept to enhance survival in patients with advanced lung cancer resistant to standard therapies.

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous non–small cell lung cancer.